{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T23:15:11Z","timestamp":1792192511395,"version":"4.4.0"},"reference-count":13,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2014,11,1]],"date-time":"2014-11-01T00:00:00Z","timestamp":1414800000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Enfermedades Infecciosas y Microbiolog\u00eda Cl\u00ednica"],"published-print":{"date-parts":[[2014,11]]},"DOI":"10.1016\/j.eimc.2014.03.014","type":"journal-article","created":{"date-parts":[[2014,6,7]],"date-time":"2014-06-07T07:15:33Z","timestamp":1402125333000},"page":"579-582","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":18,"title":["Rabdomi\u00f3lisis y hepatotoxicidad grave por interacci\u00f3n entre ritonavir y simvastatina. \u00bfPuede emplearse la estatina m\u00e1s coste-efectiva en todos los pacientes infectados por el virus de la inmunodeficiencia humana?"],"prefix":"10.1016","volume":"32","author":[{"given":"Carla","family":"Bastida","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Antonia","family":"Also","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan Manuel","family":"Pericas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emili","family":"Letang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Montse","family":"Tuset","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Josep Maria","family":"Mir\u00f3","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"Suppl III","key":"10.1016\/j.eimc.2014.03.014_bib0005","first-page":"III50","article-title":"Safety of statins: Focus on clinical pharmacokinetics and drug interactions","volume":"109","author":"Bellosta","year":"2004","journal-title":"Circulation"},{"key":"10.1016\/j.eimc.2014.03.014_bib0010","doi-asserted-by":"crossref","first-page":"e111","DOI":"10.1086\/344179","article-title":"Simvastatin-nelfinavir interaction implicated in rhabdomyolysis and death","volume":"35","author":"Hare","year":"2002","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.eimc.2014.03.014_bib0015","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1016\/j.amjcard.2004.07.080","article-title":"Comparative pharmacokinetic interaction profiles of pravastatin, simvastatin, and atorvastatin when coadministered with cytochrome P450 inhibitors","volume":"94","author":"Jacobson","year":"2004","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.eimc.2014.03.014_bib0020","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1093\/ajhp\/59.8.728","article-title":"Rhabdomyolysis due to probable interaction between simvastatin and ritonavir","volume":"59","author":"Cheng","year":"2002","journal-title":"Am J Health Syst Pharm"},{"key":"10.1016\/j.eimc.2014.03.014_bib0025","doi-asserted-by":"crossref","first-page":"411","DOI":"10.3122\/jabfm.2007.04.060187","article-title":"Severe rhabdomyolysis and acute renal failure secondary to concomitant use of simvastatin, amiodarone, and atazanavir","volume":"20","author":"Schmidt","year":"2007","journal-title":"J Am Board Fam Med"},{"key":"10.1016\/j.eimc.2014.03.014_bib0030","unstructured":"Martin CM, Hoffman V, Berggren RE. Rhabdomyolysis in a patient receiving simvastatin concurrently with highly active antiretroviral therapy. 40th Interscience Conference on Antimicrobial Agents and Chemotherapy. Toronto, Canada, Sep 17-20, 2000. Abstract 1297."},{"key":"10.1016\/j.eimc.2014.03.014_bib0035","first-page":"272","article-title":"Rhabdomyolysis: A review of the literature","volume":"67","author":"Khan","year":"2009","journal-title":"Neth J Med"},{"key":"10.1016\/j.eimc.2014.03.014_bib0040","unstructured":"Tuset M, Mir\u00f3 JM, Codina C, Ribas J, editores. Interacciones en VIH [consultado 25 Feb 2014]. Disponible en: www.interaccionesvih.com"},{"key":"10.1016\/j.eimc.2014.03.014_bib0045","unstructured":"Zocor\u00ae (simvastatina). Ficha t\u00e9cnica del producto. Laboratorios Merck Sharp and Dohme de Espa\u00f1a, S. A. Revisado abril 2013 [25 de febrero de 2014]. Disponible en: http:\/\/www.aemps.gob.es\/cima\/pdfs\/es\/ft\/58846\/FT_58846.pdf"},{"key":"10.1016\/j.eimc.2014.03.014_bib0050","unstructured":"FDA MedWatch. FDA Drug Safety Communication: Interactions between certain HIV or hepatitis C drugs and cholesterol-lowering statin drugs can increase the risk of muscle injury, 3-01-2012 [consultado 25 Feb 2014]. Disponible en: http:\/\/www.fda.gov\/Drugs\/DrugSafety\/ucm293877.htm#references"},{"key":"10.1016\/j.eimc.2014.03.014_bib0055","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1007\/s40262-013-0075-4","article-title":"Drug-drug interactions between HMG-CoA reductase inhibitors (statins) and antiviral protease inhibitors","volume":"52","author":"Chauvin","year":"2013","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.eimc.2014.03.014_bib0060","unstructured":"Ort\u00fan Rubio V (coord.), Peir\u00f3 S, Sanf\u00e9lix Gimeno G, Ridao L\u00f3pez M, Cervera Casino P. Revisi\u00f3n sistem\u00e1tica de evaluaciones econ\u00f3micas de las estatinas comercializadas en Espa\u00f1a. Ag\u00e8ncia d\u2019Avaluaci\u00f3 de Tecnologies i Recerca M\u00e8diques, 2007 [consultado 25 Feb 2014]. Disponible en: http:\/\/www20.gencat.cat\/docs\/salut\/Minisite\/catsalut\/Proveidors_professionals\/medicaments_farmacia\/farmaeconomica\/CAEIP\/informes_dictaments\/estatines\/estatinas.informe.es.CAEIP.2007.pdf"},{"key":"10.1016\/j.eimc.2014.03.014_bib0065","unstructured":"Protocol d\u2019utilitzaci\u00f3 d\u2019estatines. \u00c0rea Integral de Salut Barcelona Esquerra. Corporaci\u00f3 Sanit\u00e0ria de Barcelona [consultado 25 Feb 2014]. Disponible en: http:\/\/www.gencat.cat\/salut\/botss\/pdf\/estatines_bcn_esquerra.pdf"}],"container-title":["Enfermedades Infecciosas y Microbiolog\u00eda Cl\u00ednica"],"original-title":[],"language":"es","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0213005X14001438?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0213005X14001438?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,8,11]],"date-time":"2019-08-11T06:16:31Z","timestamp":1565504191000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0213005X14001438"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,11]]},"references-count":13,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2014,11]]}},"alternative-id":["S0213005X14001438"],"URL":"https:\/\/doi.org\/10.1016\/j.eimc.2014.03.014","relation":{},"ISSN":["0213-005X"],"issn-type":[{"value":"0213-005X","type":"print"}],"subject":[],"published":{"date-parts":[[2014,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Rabdomi\u00f3lisis y hepatotoxicidad grave por interacci\u00f3n entre ritonavir y simvastatina. \u00bfPuede emplearse la estatina m\u00e1s coste-efectiva en todos los pacientes infectados por el virus de la inmunodeficiencia humana?","name":"articletitle","label":"Article Title"},{"value":"Enfermedades Infecciosas y Microbiolog\u00eda Cl\u00ednica","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eimc.2014.03.014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier Espa\u00f1a, S.L.U. y Sociedad Espa\u00f1ola de Enfermedades Infecciosas y Microbiolog\u00eda Cl\u00ednica. All rights reserved.","name":"copyright","label":"Copyright"}]}}